Literature DB >> 3058911

Infection as a complication of heart transplantation.

J Linder1.   

Abstract

Infection and cardiac rejection are the most significant causes of morbidity and mortality after heart transplantation. At some transplant centers, more than half of the early transplantation-related deaths are the result of infection. The infectious agents may be transmitted to the host by means of the allograft, through blood transfusion, by nosocomial or environmental routes, or they may represent endogenous microbial flora or reactivation of a prior infection. The frequency of infectious complications is generally related to the degree of immunosuppressive therapy required to prevent graft rejection. Both the composition of the immunosuppressive regimen and the dosage of the immunosuppressive drugs affect the infection rate. Recent protocols, employing a combination of cyclosporine, steroids, and azathioprine cause less toxicity and lower infection rates than protocols that rely solely on cyclosporine and steroids or protocols utilized in the 1970s, which did not contain cyclosporine. A literature review of data reported from 12 transplant centers, encompassing 384 patients who received their transplantation in the era of cyclosporine, revealed infections in 221 patients (57.6%), with 20 infection-related deaths (5.2%). All classes of microorganisms infected the heart transplant recipients. The most frequent agents included staphylococci, gram-negative enteric, Nocardia (bacterial); Aspergillus, Candida, Cryptococcus (fungal); cytomegalovirus, herpes simplex, herpes zoster (viral); and Pneumocystis carinii, Toxoplasma gondii (protozoal). The respiratory tract, urinary tract, and skin were the most common sites of infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3058911

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  5 in total

1.  Endocarditis by Aspergillus fumigatus in a renal transplant.

Authors:  P Marín; P García-Martos; A García-Doncel; A García-Tapia; E Aznar; J Perez Requena; S Valverde
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Risk factors for invasive fungal disease in heart transplant recipients.

Authors:  Alexander S Rabin; Michael M Givertz; Gregory S Couper; Margaret M Shea; Driele Peixoto; Deborah S Yokoe; Lindsey R Baden; Francisco M Marty; Sophia Koo
Journal:  J Heart Lung Transplant       Date:  2014-10-02       Impact factor: 10.247

3.  In vitro and in vivo activities of syn2836, syn2869, syn2903, and syn2921: new series of triazole antifungal agents.

Authors:  S M Salama; H Atwal; A Gandhi; J Simon; M Poglod; H Montaseri; J K Khan; T Furukawa; H Saito; K Nishida; F Higashitani; T Uji; N Unemi; M Daneshtalab; R G Micetich
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Pneumocystis carinii pneumonia in heart transplant recipients.

Authors:  P Grossi; G B Ippoliti; C Goggi; P Cremaschi; M Scaglia; L Minoli
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

5.  Mediastinitis and mycotic aneurysm of the aorta after orthotopic heart transplantation.

Authors:  M Anthuber; B M Kemkes; E Kreuzer; M Gokel; A Schuetz; C Kugler; F Sudhoff
Journal:  Tex Heart Inst J       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.